Clinical Trial

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Name: Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors — clinical trial record (NCT07589205)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors

Protocol Amendment History 1 change

critical Primary endpoint(s) modified 2026-07-24

Trial Details

NCT Number	NCT07589205
Lead Sponsor	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Conditions	Solid Tumor, Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
Enrollment	493 participants
Start Date	2026-03-31
Primary Completion	2027-06-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-23